Johnson & Johnson Halts Development of JNJ-5939 for Atopic Dermatitis

Johnson & Johnson Halts Development of JNJ-5939 for Atopic Dermatitis

By, Admin 27 December 2025

Johnson & Johnson has discontinued development of its experimental eczema drug, JNJ-5939, after it failed to meet internal efficacy benchmarks.

Why JNJ-5939 Was Dropped?

JNJ-5939 was being evaluated in patients with atopic dermatitis, a chronic inflammatory skin disease marked by redness and intense itching.

According to the company:

  • The drug was well tolerated in clinical testing
  • However, it did not achieve the “high-bar” efficacy required to justify further development

As a result, Johnson & Johnson decided not to advance the programme.

Atopic Dermatitis: A Massive Unmet Need

Atopic dermatitis affects over 100 million people globally, making it one of the most common chronic inflammatory skin conditions.

Patients often struggle with:

  • Persistent itching and inflammation
  • Sleep disruption and reduced quality of life
  • Long-term dependence on systemic therapies

Despite multiple approved treatments, many patients still fail to achieve adequate disease control.

Johnson & Johnson’s Broader Eczema Pipeline

While JNJ-5939 is no longer moving forward, Johnson & Johnson emphasized its continued commitment to atopic dermatitis research.

The company is currently developing:

  • Bispecific antibodies: NM26, PX128, and PX130
  • Oral STAT6 inhibitor: KP-723

These programmes target different immune pathways involved in eczema, aiming to improve outcomes beyond existing options.

The Competitive Landscape in Eczema

Atopic dermatitis already has several established therapies on the market, including:

  • Dupixent (Sanofi / Regeneron)
  • Rinvoq (AbbVie)
  • Cibinqo (Pfizer)
  • Ebglyss (Eli Lilly)
  • Older generics such as cetirizine

This crowded landscape raises the bar for new entrants, making strong efficacy data essential.

Bottom Line

JNJ-5939’s discontinuation highlights how competitive and data-driven the atopic dermatitis space has become. For large pharma, being “safe” is no longer enough. New therapies must clearly outperform existing standards to survive development.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!